Vivos Therapeutics Reports Impressive Revenue Performance
Vivos Therapeutics, Inc. (NASDAQ: VVOS), a forward-thinking medical device company specializing in innovative solutions for sleep-related breathing disorders, has announced significant revenue growth in its latest financial results. The highlight of these results showcased an astounding 78% increase in sequential revenue from the previous quarter, marking a period of exciting operational developments for the company.
Strategic Changes Fuel Growth
The company's Chairman and CEO, Kirk Huntsman, expressed strong optimism about this positive trajectory, noting, "This increase in revenue not only demonstrates our effective execution of new business strategies but also reflects the successful transition from relying solely on a dental distribution model to embracing direct partnerships and acquisitions within the medical sleep practice sector." This strategic pivot is evident following the acquisition of The Sleep Center of Nevada, which has significantly broadened Vivos' market reach.
Operating Highlights of the Third Quarter
In financial terms, Vivos reported a revenue of $6.8 million for the third quarter of 2025, an impressive rise from $3.9 million during the same time last year. Over the nine months leading up to September 30, cumulative revenue reached $13.6 million. The clear driving force behind this surge was an increase in service and product sales tied to Vivos' strategic direction towards establishing sleep center provider relationships.
The Sleep Center of Nevada's Contribution
The Sleep Center of Nevada contributed significantly to these results, bringing in $2.2 million in diagnostic sleep testing revenue alongside $1.3 million from new service revenues associated with its treatment center operations. This acquisition allowed the company to leverage its proprietary tools and therapies directly in the marketplace more effectively.
Aiming for a Bright Future
As Vivos continues its growth journey, it anticipates further expansion in the Las Vegas region. The overwhelming patient demand experienced has led the company to book appointments for sleep tests well into early next year, showcasing a robust demand for its services. Management plans to optimize operations at SCN and is actively exploring opportunities to scale its model into additional major markets, ensuring that a broader audience can benefit from its advanced treatments.
Investment in Growth and Infrastructure
Chief Financial Officer Bradford Amman highlighted the imperative of investing in human resources and essential infrastructure to support this growth. This investment has somewhat elevated operational expenses but is expected to yield dividends in the form of increased revenues and enhanced operational efficiency as Vivos solidifies its standing in the market.
Reaffirming Commitment to Sleep Health
Vivos Therapeutics remains steadfast in its commitment to addressing sleep-related health issues. By developing innovative technologies and treatment methods, Vivos aims to empower healthcare providers to offer comprehensive solutions to obstructive sleep apnea (OSA) patients effectively.
Looking Ahead
For investors and stakeholders, Vivos will host a conference call to dive deeper into its financial results, strategic initiatives, and future plans. This call represents an opportunity for active engagement and discussion, reflecting the company's commitment to transparency and dialogue with its customer base.
Frequently Asked Questions
What was the revenue growth percentage for Vivos in Q3 2025?
Vivos reported a remarkable 78% sequential revenue growth from the previous quarter.
What factors contributed to the revenue increase in Q3 2025?
The acquisition of The Sleep Center of Nevada and a strategic pivot to direct affiliations and acquisitions within the medical sleep practices sector contributed significantly to the revenue increase.
What is the current focus of Vivos Therapeutics?
Vivos is focused on optimizing operations at its newly acquired sleep center and expanding its service offerings to meet growing patient demand.
How much revenue did The Sleep Center of Nevada generate for Vivos?
The Sleep Center of Nevada generated $2.2 million in diagnostic sleep testing revenue and an additional $1.3 million from treatment services.
What are Vivos’s expectations for the upcoming year?
The company expects to continue expanding its model into new markets and is committed to adding new sleep optimization teams to enhance operational efficiency and profitability.
